Aspect Imaging Continues to Build its World-Class Technical Leadership Team as it Prepares for Expansion into the Clinical and Advanced Industrial Markets
SHOHAM, Israel, Feb. 27, 2012 /CNW/ - Aspect Imaging, the world leading developer of high-performance compact permanent magnets, announced that Peter Bendel, PhD has joined Aspect's management team in the new position of Chief Technology Officer and Eran Toledo, PhD is to become the new Vice President, Research and Development. Oded Sherman, who is the current Vice President, Research and Development, is moving into the newly created position of Vice President, Advanced Industrial Applications.
Dr. Bendel, in his role as Chief Technology Officer, will lead Aspect Imaging's platform technology initiatives and will continue to create new technology opportunities upon which Aspect can further develop its competitive advantage. He will also continue his role on Aspect Imaging's Scientific Advisory Board. Dr. Bendel was most recently Senior Staff Scientist, Director, NMR and MRI Facilities, Department of Chemical Research Support at the Weizmann Institute of Science, Israel. He has over 30 years' of experience in the field of MRI, including having worked as R & D Physicist at Elscint, as a Visiting Scientist at the University of Tennessee Medical Center, and in the Corporate Research Laboratory of ExxonMobil. He is author of over 60 scientific papers and has been awarded several patents in the field of MRI.
Dr. Toledo is the new Vice President, Research and Development and is responsible for the day-to-day activities of the 30+-person engineering team at Aspect Imaging including advanced magnet design, software and sequence development and mechanical engineering teams. He will work closely with Dr. Bendel in managing the product roadmap for the Aspect products across the pre-clinical, clinical and industrial markets. Dr. Toledo has over 15 years of experience in the medical device field and most recently was Vice President, R&D at BSP, a medical device company focused on cardiology applications. He is a distinguished Talpiyot graduate and holds a PhD in Medical Physics from Tel Aviv University.
Mr. Sherman has transitioned to a newly-formed position of Vice President, Advanced Industrial Applications where he will lead Aspect's technology and commercial efforts in the advanced industrial marketplace with a special focus in agricultural, food processing, biofuel and process control verticals. Aspect Imaging has tier-one industrial installations and customer sites and Mr. Sherman is charged with extending Aspect's global footprint.
"Aspect Imaging has experienced significant growth both commercially and in the size and sophistication of our research and development efforts," says Uri Rapoport, Aspect Imaging's Founder and CEO. "Peter and Eran bring significant expertise in medical devices including MRI as well as commercialization and oversight of complex research initiatives and development teams. They will complement our already impressive team and will continue to accelerate Aspect's delivery of leading edge MR-based solutions to the clinical and advanced industrial markets. In addition, Oded will lead Aspect's growing penetration into the advanced industrial marketplace where there are unmet customer needs and where our technology provides significant solutions, benefits and ROI".
About Aspect Imaging:
Aspect Imaging (www.aspectimaging.com) is the world's leader in high-performance compact MRI imaging systems for pre-clinical, clinical and advanced industrial applications. In pre-clinical research, Aspect's M2™ platform and suite of products enables academic researchers and pharmaceutical companies to harness the power and insights of MRI but without the cost, complexity and technical burden of traditional MRI systems. With Aspect's integrated and simple-to-use platform, researchers can derive deep insights into their biological questions quickly, easily and cost-effectively - - and all with the push of a button. As the system has no fringe magnetic field, the M2 can be placed anywhere in a working lab including at a scientist's benchtop. The M2™ platform is used by leading institutions for a broad range of in vivo, ex vivo and in vitro applications including high-resolution 3D anatomical, molecular, functional and multi-modality imaging. The Aspect M2 high-performance MRI system is used to quantify the expression of disease, to monitor disease progression and to assess therapeutic efficacy and response.
For further information:
E. [email protected]